Results 211 to 220 of about 9,806 (254)
Some of the next articles are maybe not open access.
Plasminogen Activator Inhibitor 1 and Plasminogen Activator Inhibitor 2 in Various Disease States
Thrombosis and Haemostasis, 1988SummaryThe association of increased PA-inhibitor (PAI) activity and of PAI-1 and PAI-2 antigen levels with different pathological conditions was studied in a collective of over 300 patients. PAI-1 and PAI-2 levels were measured by specific radioimmunoassays.
Kruithof, Egbert K O +2 more
openaire +3 more sources
Neutralization by Plasminogen Activator Inhibitor-1 of Mutants of Tissue Plasminogen Activator
Enzyme, 2017Deletion mutants of human tissue plasminogen activator (tPA) were expressed in Chinese hamster ovary cells. These cells had been transfected with genes that encoded tPA but included restriction sites that allowed the deletion of DNA encoding specific structural domains of the tPA molecule’s heavy chain.
P W, Bergum, L A, Erickson
openaire +2 more sources
Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Stroke Patients
Stroke, 1996Background and Purpose Abnormal endogenous fibrinolytic activity may be a risk factor for stroke. Since the possible variation of tissue-type plasminogen activator (TPA) antigen and plasminogen activator inhibitor-1 (PAI-1) antigen concentrations over time after stroke has been rarely studied, it was examined in plasma from ...
A, Lindgren +4 more
openaire +2 more sources
Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992We have shown that the urokinase (UK) kringle domain contains a high-affinity plasminogen activator inhibitor-1 (PAI-1) binding site, responsible for the 10-fold faster complex formation between UK and PAI-1 than between PAI-1 and low-molecular-weight urokinase (LMWUK).
J, Mimuro +4 more
openaire +2 more sources
Plasminogen activator inhibitor-1 and the kidney
American Journal of Physiology-Renal Physiology, 2002Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor that was isolated 20 years ago. First recognized as an inhibitor of intravascular fibrinolysis, it is now evident that PAI-1 is a multifunctional protein with actions that may be dependent on or independent of its protease inhibitory effects.
openaire +2 more sources
Plasminogen Activators and Plasminogen Activator Inhibitor 1 in Urinary Tract Cancer
Urologia Internationalis, 2010The plasminogen activation system is considered to play an important role in cancer growth and metastasis. Both plasminogen activators (PAs) and their fast-acting inhibitors are produced in tumor cells and their surrounding tissues. In order to clarify the influence of the existence of malignant tumor in urinary tract on the systemic fibrinolytic ...
H, Bashar +8 more
openaire +2 more sources
Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence [PDF]
Experimental Gerontology, 1996 Fibroblast senescence is associated with a loss of proliferative potential and an alteration in extracellular gene expression. Because the expression of extracellular gene products are frequently growth state dependent, we undertook a comparative study ...
Michael D West +2 more
exaly +2 more sources
Plasminogen Activator Inhibitor-1
2008Fibrinolysis, the dissolution of fibrin clots, is an integral component of the hemostatic system that involves the concerted action of a complex system of zymogens, activators, and inhibitors [1]. Plasmin, the primary protease of the fibrinolysic system, digests fibrin, thereby converting insoluble clot to soluble fibrin degradation products.
Daniel T. Eitzman +2 more
openaire +1 more source
Plasminogen activator inhibitor type 1 deficiency
Haemophilia, 2008Summary. Plasminogen activator inhibitor type 1 (PAI‐1) is an important component of the coagulation system that down‐regulates fibrinolysis in the circulation. Reduced PAI‐1 levels may result in increased fibrinolysis and an associated bleeding diathesis. Clear documentation of PAI‐1 deficiency as a cause of a bleeding disorder has been rare.
R, Mehta, A D, Shapiro
openaire +2 more sources
Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets, 2007Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. Current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited.
Randal J, Westrick, Daniel T, Eitzman
openaire +2 more sources